469.65
前日終値:
$472.27
開ける:
$472.66
24時間の取引高:
1.18M
Relative Volume:
0.79
時価総額:
$120.60B
収益:
$11.10B
当期純損益:
$-988.90M
株価収益率:
-119.81
EPS:
-3.92
ネットキャッシュフロー:
$-1.26B
1週間 パフォーマンス:
+2.14%
1か月 パフォーマンス:
+5.35%
6か月 パフォーマンス:
+6.83%
1年 パフォーマンス:
-4.59%
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
VRTX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
2024-12-09 | アップグレード | Jefferies | Hold → Buy |
2024-11-14 | 開始されました | Citigroup | Buy |
2024-10-16 | 開始されました | Scotiabank | Sector Perform |
2024-10-10 | 再開されました | Raymond James | Mkt Perform |
2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
2024-06-27 | 開始されました | Redburn Atlantic | Buy |
2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
2024-02-15 | 開始されました | Wolfe Research | Outperform |
2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
2023-05-30 | 開始されました | William Blair | Outperform |
2023-05-04 | 再開されました | Piper Sandler | Overweight |
2023-03-21 | 開始されました | Bernstein | Outperform |
2023-01-18 | 開始されました | Canaccord Genuity | Hold |
2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2022-01-27 | 繰り返されました | JP Morgan | Overweight |
2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
2022-01-27 | 繰り返されました | Stifel | Hold |
2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2021-12-09 | 開始されました | Wells Fargo | Overweight |
2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
2021-09-09 | ダウングレード | Stifel | Buy → Hold |
2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
2021-07-19 | 再開されました | Wolfe Research | Outperform |
2021-07-01 | 開始されました | Raymond James | Mkt Perform |
2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
2020-12-30 | 開始されました | Daiwa Securities | Outperform |
2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2020-11-20 | 開始されました | Bernstein | Outperform |
2020-10-28 | 開始されました | UBS | Buy |
2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2020-03-04 | 開始されました | Barclays | Overweight |
2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
2019-11-12 | 開始されました | SunTrust | Buy |
2019-10-17 | 再開されました | BofA/Merrill | Buy |
2019-09-03 | アップグレード | Goldman | Neutral → Buy |
2019-08-01 | ダウングレード | Needham | Buy → Hold |
2019-05-23 | 再開されました | Citigroup | Buy |
2019-05-21 | 開始されました | Credit Suisse | Outperform |
2019-04-12 | 開始されました | Evercore ISI | In-line |
2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
How does Vertex Pharmaceuticals Incorporated generate profit in a changing economyRobust financial gains - jammulinksnews.com
Why is Vertex Pharmaceuticals Incorporated stock attracting strong analyst attentionInvest confidently with real-time data - jammulinksnews.com
Published on: 2025-07-27 22:21:17 - jammulinksnews.com
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment - MSN
Is Vertex Pharmaceuticals Incorporated a growth stock or a value stockSuperior portfolio returns - jammulinksnews.com
Should I hold or sell Vertex Pharmaceuticals Incorporated stock in 2025Free Stock Market Forecast Reports - jammulinksnews.com
Truist Financial Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know - MSN
Vertex Bets Big On Rare Diseases And Pain Medicine - Finimize
What drives Vertex Pharmaceuticals Incorporated stock priceHigh-octane financial growth - Autocar Professional
Can Vertex Pharmaceuticals Incorporated stock recover from recent declineFree Risk Assessment Services - jammulinksnews.com
Three Indian American-led firms among TIME100 Most Influential Companies - The American Bazaar
Vertex Pharmaceuticals Incorporated Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Advances Cystic Fibrosis Treatment With ALYFTREK Approval in Canada - Yahoo Finance
What analysts say about Vertex Pharmaceuticals Incorporated stockFree Stock Market Return Analysis - jammulinksnews.com
Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Cystic Fibrosis Pipeline Outlook 2025: Insights into Drug Development and Leading 50+ Companies - The Globe and Mail
Vertex Pharmaceuticals: Pioneering Orphan Drug Innovation in Cystic Fibrosis and Cementing Market Leadership - AInvest
Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis - The Malaysian Reserve
Is Vertex Pharmaceuticals Incorporated a good long term investmentTriple-digit wealth increases - jammulinksnews.com
Vertex Pharmaceuticals (VRTX) Gets a Hold from Wells Fargo - The Globe and Mail
Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need To Know - Barchart.com
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - Yahoo Finance
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
3 Monster Stocks in the Making to Buy Right Now - The Motley Fool
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga
Vertex Pharmaceuticals (VRTX): Can Strong Catalysts Propel Outperformance Ahead of Earnings? - AInvest
Lobbying Update: $1,140,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq
Diabetic Neuropathic Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca, Eli Lilly and Company - Barchart.com
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharmaceuticals: Strong Growth Driven by Cystic Fibrosis Success and Strategic Expansions - TipRanks
Vertex Pharmaceuticals Surges to 213th in Trading Volume with $460 Million in Shares Traded Despite Stock Price Decline - AInvest
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment - Yahoo Finance
England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek - insights.citeline.com
Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug - BioPharma Dive
Peripheral Neuropathic Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Trevena, Afasci, Lexicon Pharma, Haisco Pharma, Vertex Pharma - Barchart.com
EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment - Insider Monkey
Vertex secures NHS deal for once-daily cystic fibrosis therapy - The Pharma Letter
Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value - Yahoo Finance
Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE - PMLiVE
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):